This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,244,000.00 to the University of North Carolina at Chapel Hill to conduct research targeting the E3 ligase SPOP in treating renal cell carcinoma. The award period runs from July 1, 2024 to June 30, 2028. The University of North Carolina at Chapel Hill, a major public research university, has extensive experience managing large-scale federally-funded biomedical research projects. This award leverages the university's broad academic and research capabilities to advance innovative scientific studies on cancer treatments. The funding will support the university's efforts to develop and test new therapeutic approaches for renal cell carcinoma, a type of kidney cancer, by focusing on the E3 ligase SPOP as a potential target.